{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:41:30Z","timestamp":1790642490707,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":792,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>In polycystic liver (PLD) and kidney (PKD) diseases, increased cyclic adenosine monophosphate (cAMP) levels trigger hepatorenal cystogenesis. A reduction of the elevated cAMP by targeting somatostatin receptors (SSTRs) with octreotide (OCT; a somatostatin analog that preferentially binds to SSTR2) inhibits cyst growth. Here we compare the effects of OCT to pasireotide (PAS; a more potent somatostatin analog with broader receptor specificity) on: (1) cAMP levels, cell cycle, proliferation, and cyst expansion <jats:italic toggle=\"yes\">in vitro<\/jats:italic> using cholangiocytes derived from control and PCK rats (a model of autosomal recessive PKD [ARPKD]), healthy human beings, and patients with autosomal dominant PKD (ADPKD); and (2) hepatorenal cystogenesis <jats:italic toggle=\"yes\">in vivo<\/jats:italic> in PCK rats and <jats:italic toggle=\"yes\">Pkd2<\/jats:italic>\n                                 <jats:sup>\n                                    WS25\/-<\/jats:sup> mice (a model of ADPKD). Expression of SSTRs was assessed in control and cystic cholangiocytes of rodents and human beings. Concentrations of insulin-like growth factor 1 (IGF1) and vascular endothelial growth factor (VEGF) (both involved in indirect action of somatostatin analogs), and expression and localization of SSTRs after treatment were evaluated. We found that PAS was more potent (by 30%-45%) than OCT in reducing cAMP and cell proliferation, affecting cell cycle distribution, decreasing growth of cultured cysts <jats:italic toggle=\"yes\">in vitro<\/jats:italic>, and inhibiting hepatorenal cystogenesis <jats:italic toggle=\"yes\">in vivo<\/jats:italic> in PCK rats and <jats:italic toggle=\"yes\">Pkd2<\/jats:italic>\n                                 <jats:sup>\n                                    WS25\/-<\/jats:sup> mice. The levels of IGF1 (but not VEGF) were reduced only in response to PAS. Expression of SSTR1 and SSTR2 (but not SSTR3 and SSTR5) was decreased in cystic cholangiocytes compared to control. Although both OCT and PAS increased the immunoreactivity of SSTR2, only PAS up-regulated SSTR1; neither drug affected cellular localization of SSTRs. <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: PAS is more effective than OCT in reducing hepatorenal cystogenesis in rodent models; therefore, it might be more beneficial for the treatment of PKD and PLD. (HEPATOLOGY 2013)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26140","type":"journal-article","created":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T20:21:09Z","timestamp":1353529269000},"page":"409-421","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":94,"title":["Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases"],"prefix":"10.1097","volume":"58","author":[{"given":"Tatyana V.","family":"Masyuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brynn N.","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Stroope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas M.","family":"Banales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Gradilone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoliy I.","family":"Masyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas F.","family":"LaRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-43-20241201","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MOG.0b013e328328f4ff","article-title":"Cholangiociliopathies: genetics, molecular mechanisms and potential therapies.","volume":"25","author":"Masyuk","year":"2009","journal-title":"Curr Opin Gastroenterol"},{"key":"R3-43-20241201","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MOG.0b013e328343433f","article-title":"Somatostatin analogues for treatment of polycystic liver disease.","volume":"27","author":"Gevers","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"R4-43-20241201","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1196\/annals.1294.012","article-title":"Molecular signaling of somatostatin receptors.","volume":"1014","author":"Lahlou","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"R6-43-20241201","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/gut.2003.036053","article-title":"Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.","volume":"53","author":"Reynaert","year":"2004","journal-title":"Gut"},{"key":"R7-43-20241201","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3,5cyclic monophosphate.","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"R8-43-20241201","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R9-43-20241201","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of longacting somatostatin for autosomal dominant polycystic kidney and liver disease.","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R10-43-20241201","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of longacting somatostatin treatment in autosomaldominant polycystic kidney disease.","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"R11-43-20241201","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The longterm outcome of patients with polycystic liver disease treated with lanreotide.","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R12-43-20241201","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): development, mechanism of action and potential applications.","volume":"286","author":"Schmid","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"R13-43-20241201","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1756-9966-29-19","article-title":"Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.","volume":"29","author":"Appetecchia","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"R14-43-20241201","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1369\/jhc.2008.950998","article-title":"Expression of somatostatin and somatostatin receptor subtypes 15 in human normal and diseased kidney.","volume":"56","author":"Bhandari","year":"2008","journal-title":"J Histochem Cytochem"},{"key":"R15-43-20241201","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1210\/en.2002-220219","article-title":"SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormoneinsulinlike growth factorI axis in rats, primates, and dogs.","volume":"143","author":"Weckbecker","year":"2002","journal-title":"Endocrinology"},{"key":"R16-43-20241201","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2353\/ajpath.2008.070293","article-title":"Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease.","volume":"172","author":"Alvaro","year":"2008","journal-title":"Am J Pathol"},{"key":"R17-43-20241201","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1530\/JOE-11-0224","article-title":"Effects of somatostatin analogs on glucose homeostasis in rats.","volume":"212","author":"Schmid","year":"2011","journal-title":"J Endocrinol"},{"key":"R18-43-20241201","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/hep.22015","article-title":"Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development.","volume":"47","author":"Fabris","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R19-43-20241201","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/hep.23511","article-title":"Mammalian target of rapamycin regulates vascular endothelial growth factordependent liver cyst growth in polycystin2defective mice.","volume":"51","author":"Spirli","year":"2010","journal-title":"HEPATOLOGY"},{"key":"R21-43-20241201","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jc.2008-1919","article-title":"Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.","volume":"94","author":"Lesche","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-43-20241201","first-page":"36","article-title":"Preclinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.","volume":"28","author":"Hofland","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"R23-43-20241201","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1210\/jc.2008-1712","article-title":"Effects of somatostatin analogs on a growth hormonereleasing hormone secreting bronchial carcinoid, in vivo and in vitro studies.","volume":"94","author":"van Hoek","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-43-20241201","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1177\/147323000903700617","article-title":"Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.","volume":"37","author":"MartinezAlonso","year":"2009","journal-title":"J Int Med Res"},{"key":"R25-43-20241201","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1677\/JME-08-0012","article-title":"Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells.","volume":"40","author":"Pasquali","year":"2008","journal-title":"J Mol Endocrinol"},{"key":"R26-43-20241201","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2265.2004.02098.x","article-title":"Inhibition of endothelial proliferation by the somatostatin analogue SOM230.","volume":"61","author":"Adams","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R27-43-20241201","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/ENDO:20:3:255","article-title":"Somatostatin and somatostatin receptor physiology.","volume":"20","author":"Barnett","year":"2003","journal-title":"Endocrine"},{"key":"R29-43-20241201","doi-asserted-by":"crossref","first-page":"9343","DOI":"10.1073\/pnas.94.17.9343","article-title":"Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.","volume":"94","author":"Cordelier","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R30-43-20241201","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1210\/endo.137.9.8756582","article-title":"Agonistdependent regulation of cloned human somatostatin receptor types 15 (hSSTR15): subtype selective internalization or upregulation.","volume":"137","author":"Hukovic","year":"1996","journal-title":"Endocrinology"},{"key":"R31-43-20241201","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1507\/endocrj.52.605","article-title":"Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study.","volume":"52","author":"Taniyama","year":"2005","journal-title":"Endocr J"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26140","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201307000-00043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T14:14:14Z","timestamp":1733062454000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201307000-00043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26140","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}